In the clinical genetics setting, BRCA1 penetrance to 80 years of 79.5% (95%CI 75.5–83.5%) for breast cancer and 65% (95%CI 75–84%) for ovarian cancer are reported [36], whereas population cohorts indicate lower risks. The gene discussed is BRCA1; the disease is breast cancer.